Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 11/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.47 |
| ▸ | CMA1 | P23946 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10299169 | 1.00 | ELANE (0.51) | ELANECYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL23969592 | 0.91 | ELANE (0.53) | ELANECMA1 | |
| SCHEMBL3265287 | 0.91 | ELANE (0.52) | ELANECYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL5992849 | 0.91 | ELANE (0.52) | ELANECYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL10299121 | 0.90 | KCNH2 (0.44) | ELANECYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL5987813 | 0.90 | KCNH2 (0.44) | ELANECYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL20643721 | 0.89 | ELANE (0.49) | ELANECYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL20510150 | 0.88 | ELANE (0.48) | ELANECYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL20510148 | 0.88 | ELANE (0.48) | ELANECYP3A4CYP2C9KCNH2NR1I2 | |
| SCHEMBL24224215 | 0.88 | ELANE (0.48) | ELANECYP3A4CYP2C9KCNH2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20100317568-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317568-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | ELANE 986/4885CYP3A4 1792/4885CYP2C9 3780/4885 |
| US-20100267634-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | ELANE 986/4885CYP3A4 1792/4885CYP2C9 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.